THEBIO
- Grafting ProEn Therapeutics' 'ArtBody Platform' and RayMed's 'RayVision Solution'
- Collaboration aims to develop patient-tailored radiopharmaceuticals with high tumor selectivity and optimal dose output
[by Kang, In Hyo] ProEn Therapeutics, a company specializing in the development of novel anticancer drugs, announced on November 13 that it has signed a memorandum of understanding (MOU) with RayMed, a company dedicated to the development of customized anticancer treatment planning solutions, to develop precision radiopharmaceuticals.
The agreement aims to create more precise, patient-tailored radiopharmaceuticals by combining RayMed’s advanced anticancer treatment planning solution, RayVision, with ProEn Therapeutics’ target binder discovery platform, ‘ArtBody.’
Leading global pharmaceutical companies like Novartis, Eli Lilly, and Sanofi have been quickly adopting ‘alpha radioisotopes (α-radio isotopes)’ following the use of ‘beta rays’, which emit powerful energy. However, radiopharmaceuticals using these isotopes need a development strategy that can selectively target only cancer cells with a minimum dose. Until recently, most radiopharmaceutical binders (ligands) were limited to peptides or small molecule compounds, restricting their ability to target a broader range of tumor types.
ProEn Therapeutics' ArtBody platform is a development technology for a 'dual target simultaneous binding binder,' which is designed to simultaneously recognize and target two different types of tumor-associated antigens. This protein is engineered to have very high tumor selectivity and superior pharmacodynamic properties compared to antibodies, which are a key safety measure for radiopharmaceuticals. Therefore, the company anticipates that, beyond the limited tumor targets achievable with peptides or small molecule compounds, this platform will enable the development of radiopharmaceuticals that can target a broader range of tumors.
RayMed's RayVision solution is an artificial intelligence (AI)-powered software designed to create the optimal treatment plan for radiopharmaceuticals. It includes a feature that can simulate both the therapeutic effects and potential side effects based on the radiopharmaceutical dose administered, allowing for the calculation of the most effective and safe dose. Additionally, the solution can quickly assess the efficacy and safety of candidate substances during the preclinical phase of radiopharmaceuticals, helping to significantly reduce the time and cost associated with selecting candidate substances. The company states that this capability is expected to streamline the discovery of promising candidates in early stages of novel drug development and accelerate the development process speed.
Through this collaboration, the two companies aim to achieve tangible business results in addition to advancing research and development (R&D), focusing on developing optimal radiopharmaceuticals for alpha radioisotopes.
“We are thrilled to proceed with the development of precision radiopharmaceuticals by combining the technologies of both companies to prioritize safety, which is fundamental to radiopharmaceuticals,” said Lee Il-han, CEO of ProEn Therapeutics. “Through this MOU, we aim to establish a collaborative framework that fosters both technological and business synergies, as well as R&D.”
“We believe that the technologies of both companies will enable the creation of next-generation radiopharmaceuticals that reduce side effects and maximize effectiveness,” remarked Kim Young-hyun, CEO of RayMed. “We will strive to achieve the goal of developing patient-tailored precision radiopharmaceuticals by incorporating our company’s ‘micro-dosimetry’ technology.”
THEBIO
- Grafting ProEn Therapeutics' 'ArtBody Platform' and RayMed's 'RayVision Solution'
- Collaboration aims to develop patient-tailored radiopharmaceuticals with high tumor selectivity and optimal dose output
[by Kang, In Hyo] ProEn Therapeutics, a company specializing in the development of novel anticancer drugs, announced on November 13 that it has signed a memorandum of understanding (MOU) with RayMed, a company dedicated to the development of customized anticancer treatment planning solutions, to develop precision radiopharmaceuticals.
The agreement aims to create more precise, patient-tailored radiopharmaceuticals by combining RayMed’s advanced anticancer treatment planning solution, RayVision, with ProEn Therapeutics’ target binder discovery platform, ‘ArtBody.’
Leading global pharmaceutical companies like Novartis, Eli Lilly, and Sanofi have been quickly adopting ‘alpha radioisotopes (α-radio isotopes)’ following the use of ‘beta rays’, which emit powerful energy. However, radiopharmaceuticals using these isotopes need a development strategy that can selectively target only cancer cells with a minimum dose. Until recently, most radiopharmaceutical binders (ligands) were limited to peptides or small molecule compounds, restricting their ability to target a broader range of tumor types.
ProEn Therapeutics' ArtBody platform is a development technology for a 'dual target simultaneous binding binder,' which is designed to simultaneously recognize and target two different types of tumor-associated antigens. This protein is engineered to have very high tumor selectivity and superior pharmacodynamic properties compared to antibodies, which are a key safety measure for radiopharmaceuticals. Therefore, the company anticipates that, beyond the limited tumor targets achievable with peptides or small molecule compounds, this platform will enable the development of radiopharmaceuticals that can target a broader range of tumors.
RayMed's RayVision solution is an artificial intelligence (AI)-powered software designed to create the optimal treatment plan for radiopharmaceuticals. It includes a feature that can simulate both the therapeutic effects and potential side effects based on the radiopharmaceutical dose administered, allowing for the calculation of the most effective and safe dose. Additionally, the solution can quickly assess the efficacy and safety of candidate substances during the preclinical phase of radiopharmaceuticals, helping to significantly reduce the time and cost associated with selecting candidate substances. The company states that this capability is expected to streamline the discovery of promising candidates in early stages of novel drug development and accelerate the development process speed.
Through this collaboration, the two companies aim to achieve tangible business results in addition to advancing research and development (R&D), focusing on developing optimal radiopharmaceuticals for alpha radioisotopes.
“We are thrilled to proceed with the development of precision radiopharmaceuticals by combining the technologies of both companies to prioritize safety, which is fundamental to radiopharmaceuticals,” said Lee Il-han, CEO of ProEn Therapeutics. “Through this MOU, we aim to establish a collaborative framework that fosters both technological and business synergies, as well as R&D.”
“We believe that the technologies of both companies will enable the creation of next-generation radiopharmaceuticals that reduce side effects and maximize effectiveness,” remarked Kim Young-hyun, CEO of RayMed. “We will strive to achieve the goal of developing patient-tailored precision radiopharmaceuticals by incorporating our company’s ‘micro-dosimetry’ technology.”